News

Fatty liver disease, also called metabolic dysfunction-associated steatohepatitis (MASH), is a condition where fat ...
Scientists are continuing to find evidence that GLP-1 medications can temper cravings for alcohol and other drugs.
Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...
Discover Veru Inc.'s Q2 2025 earnings highlights, including enobosarm's promising Phase 2b results in weight management, funding plans, and ...
Mounjaro and Ozempic are two medications that can help with diabetes and weight management. But is there a winner in the ...
Attorney James Gourley details the many legal issues surrounding the GLP-1 drug market and offers advice to companies on how ...
Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...
It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...
The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day ...
Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.